View Older Stories View More Recent Stories
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $60 at Leerink Partners
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $60 at Scotiabank
-
Bristol-Myers Squibb (BMY) call put ratio 1.5 calls to 1 put into the annual J.P. Morgan Healthcare Conference
-
UBS Assumes and Upgrades Bristol-Myers Squibb Co. (BMY) at Buy
-
Guggenheim Reiterates Buy Rating on Bristol-Myers Squibb Co. (BMY)
-
Bristol Myers Squibb strikes deal with US government on drug pricing
-
14 of 17 Leading Drug Manufactures Now Part of Trump Most Favored Nation Efforts
-
Bristol Myers receives FDA orphan drug designation for systemic sclerosis
-
BofA Securities Upgrades Bristol-Myers Squibb Co. (BMY) to Buy
-
Guggenheim Upgrades Bristol-Myers Squibb Co. (BMY) to Buy
-
Bristol-Myers Squibb (BMY) Raises Quarterly Dividend 1.6% to $0.63; 4.9% Yield
-
Bristol Myers Squibb presents lymphoma research data at ASH 2025
-
FDA approves Bristol Myers Squibb Breyanzi for marginal zone lymphoma
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $53 at Scotiabank
-
Truist Securities on Bristol-Myers Squibb Co. (BMY): 'overall positive'
-
Bristol Myers Squibb presents hematology pipeline data at ASH 2025
-
Bernstein on IRA pricing: $245 really is the floor
-
Guggenheim Reiterates Neutral Rating on Bristol-Myers Squibb Co. (BMY)
-
Bristol-Myers Squibb (BMY) call put ratio1.7 calls to 1 put amid price movement
-
Bristol Myers Squibb gains European approval for Breyanzi in mantle cell lymphoma
-
Bristol-Myers Squibb's (BMY) Milvexian Can Reset Sentiment - Cantor Fitzgerald
-
Bristol-Myers Squibb's (BMY) Milvexian Can Reset Sentiment Positively - Cantor Fitzgerald
-
BMO Capital: 'Bristol-Myers Squibb (BMY) Management Paints a Path Through Near-Term Catalysts'
-
Bristol Myers Squibb accepts $7.5 billion in debt tender offers
-
BMO Capital on Bristol-Myers Squibb (BMY): 'LIBREXIA-ACS Discontinuation Places More Weight on Remaining Programs'
-
Piper Sandler on Bristol-Myers Squibb Co. (BMY): 'Milvexian Did Strike Us As High-Risk'
-
Bernstein on Bristol-Myers Squibb Co. (BMY): 'Key Catalysts Carrying More Risk Than Ever'
-
Sarah Cannon Research Institute expands collaboration with Bristol Myers Squibb
-
Bristol-Myers Squibb Co. (BMY) PT Lowered to $62 at Piper Sandler
-
Bristol Myers Squibb prices €5 billion senior unsecured notes offering
-
Bristol Myers Squibb presents CAMZYOS data at heart association meeting
-
Bernstein on Bristol-Myers Squibb Co. (BMY): 'All Eyes on Cobenfy's ADEPT-2'
-
Metsera Was Previously in Exclusive Talks with Bristol-Myers Squibb, Sources Say -- WSJ
-
Bristol-Myers Squibb ups annual outlook as Q3 print exceeds estimates
-
Bristol-Myers Squibb (BMY) Tops Q3 EPS by 11c; lifts outlook
-
Bristol Myers Squibb shows long-term Sotyktu efficacy data
-
Evotec receives $25 million from Bristol Myers Squibb for neuroscience work
-
Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb
-
SystImmune and Bristol Myers Squibb report phase I trial results for cancer drug
-
insitro extends Bristol Myers Squibb collaboration for ALS drug discovery
-
Bristol Myers Squibb to acquire Orbital Therapeutics for $1.5 billion
-
Bristol-Myers Squibb (BMY) call put ratio 3.9 calls to 1 put with a focus on a spreader of 10K contracts of November 48 and 52.50 calls
-
BMS-986446 receives FDA fast track designation for alzheimer's treatment
-
CFRA Upgrades Bristol-Myers Squibb Co. (BMY) to Buy
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
-
Bristol Myers Squibb gets FDA fast track for alzheimer's drug candidate
-
Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
-
Bristol Myers Squibb expands direct-to-patient drug sales program
-
Stifel on Veeva Systems (VEEV): 'today's announcement is not incremental'
